MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use of nerve stimulation as a potential treatment for Crohn’s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease (IBD). This study marks a significant milestone for the company, which was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) earlier this year for its bioelectronic technology targeting the treatment of IBD. read more
Author: Rutali Thakur
Merck said on Sunday it will buy Prometheus Biosciences for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up its presence in immunology. Merck will pay $200 per share for the California-based biotechnology company that specializes in treatments for autoimmune diseases, representing a 75.4% premium to Prometheus’ last closing price. Shares of Prometheus were trading at $194.49 before the bell on Monday. “This is allowing us to move into immunology in a strong way and will allow us sustainable growth, we think, well into the 2030s given the long patent life,” Merck Chief Executive…
Two of the most important goals in the treatment of patients with inflammatory bowel disease are to improve patient quality of life and increases the odds of remission. Patients with IBD want to be able to travel without limitations, predict flares without invasive testing, and manage symptoms without being restricted to immune-suppressing options. Fortunately, new resources and advancements including IBD Passport, a website with information for travelers with IBD, wearable technology to monitor symptoms, and an increased emphasis on dietitian’s role in multidisciplinary care are making patient desires even more attainable. read more
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United States Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro…
HIMSS 2023 kicked off Monday in Chicago. Follow our live blog for the latest updates and happenings from the conference. Epic Systems is working with Microsoft to integrate generative AI technology into its electronic health record software for the first time, the companies said Monday. The announcement was made in conjunction with the first day of the HIMSS conference, which is being held in Chicago this week. read more
The US Food and Drug Administration (FDA) has granted Fast Track designation for Agenus’ combination therapy for the treatment of colorectal cancer. The FDA awarded the Fast Track status for the investigation of a botensilimab (AGEN1181) and balstilimab (AGEN2034) combination. The combination therapy has been approved to treat non-microsatellite instability-high (non-MSI-H)/deficient mismatch repair metastatic colorectal cancer patients, with no signs of active liver involvement. read More
One-third of pediatric gastroenterologists are experiencing professional burnout, according to the results of a new survey published by authors from the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) task force investigating burnout in the field. The 35-item survey was sent to 1,791 NASPGHAN members, 408 (22.7%) of whom returned the survey. A total of 28.8% reported being at high risk for emotional exhaustion, 17.5% reported high risk for depersonalization, and 33% reported overall burnout. Younger pediatric gastroenterologists appeared to be at particular risk for burnout, with survey respondents who were 44 years of age or younger reporting…
Rapid blood test sensitive to advanced adenomas could improve patient prognosis and ultimately reduce mortality ORLANDO, Fla.–(BUSINESS WIRE)– Dxcover Limited, a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today presented new data in a presentation titled “Early Detection and Molecular Markers of Prevention” on the detection of colorectal cancer (CRC) using the company’s liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida from April 14-19. Co-founder and CTO Matthew Baker, PhD, outlined data from a preclinical study evaluating the Dxcover® Cancer Liquid Biopsy platform’s capabilities to…
Meridian Bioscience has announced FDA 510(k) clearance of its Curian Shiga Toxin assay intended for detection and differentiation of Shiga toxin 1 and 2 within a single device, according to a company release. By adding Shiga toxin detection, the company has expanded the platform’s foodborne immunofluorescent testing capabilities beyond Campylobacter. read more
Irritable bowel syndrome impacts between 25 and 45 million people in the U.S., causing symptoms including severe abdominal pain and altered bowel habits. A number of famous athletes, musicians and sports stars deal with the disease every day. Ten celebrities with IBS: Sports Franklin Gutierrez. Former Seattle Mariners center fielder Franklin Gutierrez was diagnosed with IBS in 2011 after experiencing severe stomach pain. Music Cam’ron. In 2006, rapper Cam’ron released “I.B.S.,” a song detailing his experience with IBS. Cher. Singer Cher has had IBS for years and has managed symptoms by altering her diet and practicing yoga. read more